Cellular therapies in trauma and critical care medicine: Looking towards the future

1. Langan NR, Eckert M, Martin MJ. Changing patterns of in-hospital deaths following implementation of damage control resuscitation practices in US forward military treatment facilities. JAMA Surg. 2014;149(9):904–12. doi: 10.1001/jamasurg.2014.940 25029432

2. Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471–82. doi: 10.1001/jama.2015.12 25647203

3. Holcomb JB, Hoyt DB. Comprehensive injury research. JAMA. 2015;313(14):1463–4. doi: 10.1001/jama.2014.16802 25871672

4. Rasmussen TE, Baer DG, Doll BA, Caravalho J Jr. In the 'Golden Hour'. Army AL&T. Jan-Mar 2015:80–5.

5. Pati S, Pilia M, Grimsley JM, Karanikas AT, Oyeniyi B, Holcomb JB, et al. Cellular Therapies in Trauma and Critical Care Medicine: Forging New Frontiers. Shock. 2015;44(6):505–23. doi: 10.1097/SHK.0000000000000482 26428845

6. Kuhns WJ. Blood Transfusion in the Civil War. Transfusion. 1965;5:92–4. 14255506

7. Weld SB. Surgeon Bentley and the first human blood transfusion. Connecticut Medicine. 1973;37(8):423–4. 4580235

8. Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med. 2004;14(6):1035–41. 15547670

9. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol. 2005;289(1):F31–42. doi: 10.1152/ajprenal.00007.2005 15713913

10. Westenfelder C, Togel FE. Protective actions of administered mesenchymal stem cells in acute kidney injury: relevance to clinical trials. Kidney Int Suppl. 2011;1(3):103–6. doi: 10.1038/kisup.2011.24 25018910

11. Hannoush EJ, Elhassan I, Sifri ZC, Mohr AA, Alzate WD, Livingston DH. Role of bone marrow and mesenchymal stem cells in healing after traumatic injury. Surgery. 2013;153(1):44–51. doi: 10.1016/j.surg.2012.06.020 22862904

12. Granero-Molto F, Weis JA, Longobardi L, Spagnoli A. Role of mesenchymal stem cells in regenerative medicine: application to bone and cartilage repair. Expert Opin Biol Ther. 2008;8(3):255–68. doi: 10.1517/14712598.8.3.255 18294098

13. Lewis CJ. Stem cell application in acute burn care and reconstruction. J Wound Care. 2013;22(1):7–8, 10, 2–6. doi: 10.12968/jowc.2013.22.1.7 23299352

14. Badiavas AR, Badiavas EV. Potential benefits of allogeneic bone marrow mesenchymal stem cells for wound healing. Expert Opin Biol Ther. 2011;11(11):1447–54. doi: 10.1517/14712598.2011.606212 21854302

15. Asatrian G, Pham D, Hardy WR, James AW, Peault B. Stem cell technology for bone regeneration: current status and potential applications. Stem Cells Cloning. 2015;8:39–48. doi: 10.2147/SCCAA.S48423 25709479

16. Liu KD, Wilson JG, Zhuo H, Caballero L, McMillan ML, Fang X, et al. Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Ann Intensive Care. 2014;4:22. doi: 10.1186/s13613-014-0022-z 25593740

17. Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3(1):24–32. doi: 10.1016/S2213-2600(14)70291-7 25529339

18. Walker PA, Bedi SS, Shah SK, Jimenez F, Xue H, Hamilton JA, et al. Intravenous multipotent adult progenitor cell therapy after traumatic brain injury: modulation of the resident microglia population. J Neuroinflammation. 2012;9:228. doi: 10.1186/1742-2094-9-228 23020860

19. Bedi SS, Walker PA, Shah SK, Jimenez F, Thomas CP, Smith P, et al. Autologous bone marrow mononuclear cells therapy attenuates activated microglial/macrophage response and improves spatial learning after traumatic brain injury. J Trauma Acute Care Surg. 2013;75(3):410–6. doi: 10.1097/TA.0b013e31829617c6 23928737

20. Liao GP, Harting MT, Hetz RA, Walker PA, Shah SK, Corkins CJ, et al. Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children. Pediatr Crit Care Med. 2015;16(3):245–55. doi: 10.1097/PCC.0000000000000324 25581630

21. Cox CS Jr, Hetz RA, Liao GP, Aertker BM, Ewing-Cobbs L, Juranek J, et al. Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells. Stem Cells. 2017;35(4):1065–79. doi: 10.1002/stem.2538 27800660

22. Matthay MA, Pati S, Lee JW. Concise Review: Mesenchymal Stem (Stromal) Cells: Biology and Preclinical Evidence for Therapeutic Potential for Organ Dysfunction Following Trauma or Sepsis. Stem Cells. 2017;35(2):316–24. doi: 10.1002/stem.2551 27888550

23. Mothe AJ, Tator CH. Advances in stem cell therapy for spinal cord injury. J Clin Invest. 2012;122(11):3824–34. doi: 10.1172/JCI64124 23114605

24. Maron-Gutierrez T, Laffey JG, Pelosi P, Rocco PR. Cell-based therapies for the acute respiratory distress syndrome. Curr Opin Crit Care. 2014;20(1):122–31. doi: 10.1097/MCC.0000000000000061 24300620

25. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76. doi: 10.1016/j.cell.2006.07.024 16904174

26. Priest CA, Manley NC, Denham J, Wirth ED 3rd, Lebkowski JS. Preclinical safety of human embryonic stem cell-derived oligodendrocyte progenitors supporting clinical trials in spinal cord injury. Regen Med. 2015;10(8):939–58. doi: 10.2217/rme.15.57 26345388

27. Lee JW, Fang X, Krasnodembskaya A, Howard JP, Matthay MA. Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells. 2011;29(6):913–9. doi: 10.1002/stem.643 21506195

28. Tisherman SA, Schmicker RH, Brasel KJ, Bulger EM, Kerby JD, Minei JP, et al. Detailed description of all deaths in both the shock and traumatic brain injury hypertonic saline trials of the Resuscitation Outcomes Consortium. Ann Surg. 2015;261(3):586–90. doi: 10.1097/SLA.0000000000000837 25072443

29. Holcomb JB, Pati S. Optimal trauma resuscitation with plasma as the primary resuscitative fluid: the surgeon's perspective. Hematology Am Soc Hematol Educ Program. 2013;2013:656–9. doi: 10.1182/asheducation-2013.1.656 24319247

30. Jenkins DH, Rappold JF, Badloe JF, Berseus O, Blackbourne L, Brohi KH, et al. THOR Position Paper on Remote Damage Control Resuscitation: Definitions, Current Practice and Knowledge Gaps. Shock. 2014;41(01): 3–12.

31. Duckworth JL, Grimes J, Ling GS. Pathophysiology of battlefield associated traumatic brain injury. Pathophysiology. 2013;20(1):23–30. doi: 10.1016/j.pathophys.2012.03.001 22703708

32. Pati S, Khakoo AY, Zhao J, Jimenez F, Gerber MH, Harting M, et al. Human mesenchymal stem cells inhibit vascular permeability by modulating vascular endothelial cadherin/beta-catenin signaling. Stem Cells Dev. 2011;20(1):89–101. doi: 10.1089/scd.2010.0013 20446815

33. Menge T, Zhao Y, Zhao J, Wataha K, Gerber M, Zhang J, et al. Mesenchymal stem cells regulate blood-brain barrier integrity through TIMP3 release after traumatic brain injury. Sci Transl Med. 2012;4(161):161ra50. doi: 10.1126/scitranslmed.3004660 23175708

34. Mahmood A, Lu D, Lu M, Chopp M. Treatment of traumatic brain injury in adult rats with intravenous administration of human bone marrow stromal cells. Neurosurgery. 2003;53(3):697–702; discussion 702–3. 12943585

35. Cox CS Jr, Baumgartner JE, Harting MT, Worth LL, Walker PA, Shah SK, et al. Autologous bone marrow mononuclear cell therapy for severe traumatic brain injury in children. Neurosurgery. 2011;68(3):588–600. doi: 10.1227/NEU.0b013e318207734c 21192274

36. Ewing-Cobbs L, Johnson CP, Juranek J, DeMaster D, Prasad M, Duque G, et al. Longitudinal diffusion tensor imaging after pediatric traumatic brain injury: Impact of age at injury and time since injury on pathway integrity. Hum. Brain Mapp. 2016;37(11):3929–45. doi: 10.1002/hbm.23286 27329317

37. Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg. 1991;75(1):15–26. doi: 10.3171/jns.1991.75.1.0015 2045903

38. Enzmann GU, Benton RL, Talbott JF, Cao Q, Whittemore SR. Functional considerations of stem cell transplantation therapy for spinal cord repair. J Neurotrauma. 2006;23(3–4):479–95. doi: 10.1089/neu.2006.23.479 16629631

39. Fehlings MG, Vawda R. Cellular treatments for spinal cord injury: the time is right for clinical trials. Neurotherapeutics. 2011;8(4):704–20. doi: 10.1007/s13311-011-0076-7 22002087

40. Sahni V, Kessler JA. Stem cell therapies for spinal cord injury. Nat Rev Neurol. 2010;6(7):363–72. doi: 10.1038/nrneurol.2010.73 20551948

41. Brower V. BioTime acquires Geron's stem cell program. Nat Biotechnol. 2013;31(2):94. doi: 10.1038/nbt0213-94a 23392496

42. Wilson J, McKenna D, Liu KD, Matthay MA. Mesenchymal stem (stromal) cells for treatment of acute respiratory distress syndrome—authors' reply. Lancet Respir Med. 2015;3(4):e12–3. doi: 10.1016/S2213-2600(15)00040-5

43. Matthay MA, Anversa P, Bhattacharya J, Burnett BK, Chapman HA, Hare JM, et al. Cell Therapy for Lung Diseases. Report from an NIH-NHLBI Workshop, November 13–14, 2012. Am J Respir Crit Care Med. 2013;188(3):370–5. doi: 10.1164/rccm.201303-0522WS 23713908

44. Walter J, Ware LB, Matthay MA. Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet Respir Med. 2014;2(12):1016–26. doi: 10.1016/S2213-2600(14)70217-6 25465643

45. Knoepfler PS. From bench to FDA to bedside: US regulatory trends for new stem cell therapies. Adv Drug Deliv Rev. 2015;82–83:192–6. doi: 10.1016/j.addr.2014.12.001 25489841

46. Fink DW Jr. FDA regulation of stem cell-based produCT. Science. 2009;324(5935):1662–3. doi: 10.1126/science.1173712 19556496

47. Mann EA, Baun MM, Meininger JC, Wade CE. Comparison of mortality associated with sepsis in the burn, trauma, and general intensive care unit patient: a systematic review of the literature. Shock. 2012;37(1):4–16. doi: 10.1097/SHK.0b013e318237d6bf 21941222

48. Li MD, Atkins H, Bubela T. The global landscape of stem cell clinical trials. Regen Med. 2014;9(1):27–39. doi: 10.2217/rme.13.80 24236476

49. Meyfroidt G, Taccone FS. Another failed attempt of neuroprotection: progesterone for moderate and severe traumatic brain injury. Minerva anestesiologica. 2016;82(4):486–91. 26126980

50. Hawryluk GW, Bullock MR. Past, Present, and Future of Traumatic Brain Injury Research. Neurosurg Clin N Am. 2016;27(4):375–96. doi: 10.1016/j.nec.2016.05.002 27637391

51. Stein DG, Geddes RI, Sribnick EA. Recent developments in clinical trials for the treatment of traumatic brain injury. Handb Clin Neurol. 2015;127:433–51. doi: 10.1016/B978-0-444-52892-6.00028-3 25702233

52. Simon DW, McGeachy MJ, Bayir H, Clark RS, Loane DJ, Kochanek PM. The far-reaching scope of neuroinflammation after traumatic brain injury. Nat Rev Neurol. 2017;13(3):171–91. doi: 10.1038/nrneurol.2017.13 28186177